ARDX - Ardelyx, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.59
-0.41 (-6.83%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.00
Open5.81
Bid5.70 x 1300
Ask6.20 x 1200
Day's Range5.57 - 6.05
52 Week Range2.10 - 8.81
Volume645,237
Avg. Volume850,237
Market Cap497.117M
Beta (5Y Monthly)2.10
PE Ratio (TTM)N/A
EPS (TTM)-1.47
Earnings DateMar 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
  • Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
    PR Newswire

    Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors

    Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Onaiza Cadoret-Manier, an industry veteran with deep biopharmaceutical commercial experience, has joined the Company's Board of Directors. Ms. Cadoret-Manier replaces Annalisa Jenkins, who stepped down from the board effective March 12, 2020 in order to be closer and more involved with her Board responsibilities in Europe.

  • Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt
    Simply Wall St.

    Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates
    Zacks

    Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates

    Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 221.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
    PR Newswire

    Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2019.

  • Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
    Zacks

    Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

    Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference
    PR Newswire

    Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference

    Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the Cowen and Company 40th Annual Health Care Conference at 8:00 a.m. ET on Wednesday, March 4, 2020 in Boston, MA.

  • Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference
    PR Newswire

    Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 3:30 p.m. ET on Wednesday, Feb. 26, 2020 in New York City.

  • How Ardelyx, Inc. (NASDAQ:ARDX) Can Impact Your Portfolio Volatility
    Simply Wall St.

    How Ardelyx, Inc. (NASDAQ:ARDX) Can Impact Your Portfolio Volatility

    If you're interested in Ardelyx, Inc. (NASDAQ:ARDX), then you might want to consider its beta (a measure of share...

  • Benzinga

    The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...

  • Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
    PR Newswire

    Ardelyx Announces Pricing of Upsized Public Offering of Common Stock

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.25 per share, before underwriting discounts and commissions, for gross proceeds of $125,000,000. In addition, Ardelyx has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 3,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 9, 2019, subject to customary closing conditions.

  • Ardelyx Announces Proposed Public Offering of Common Stock
    PR Newswire

    Ardelyx Announces Proposed Public Offering of Common Stock

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition, Ardelyx intends to grant the underwriters of the offering the right for a period of 30 days to purchase up to an additional $12,000,000 of shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • Benzinga

    The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...

  • Reuters

    UPDATE 2-Ardelyx drug reduces elevated phosphate levels, late-stage study shows

    Ardelyx Inc's experimental drug has shown promise in a late-stage study as a standalone therapy to reduce elevated blood phosphate levels in patients with chronic kidney disease (CKD), the drugmaker said on Tuesday. While investor concern is likely over the higher-than-anticipated discontinuation rate, the results were positive with the drug, tenapanor, hitting the key goal of phosphate lowering, Piper Jaffray analyst Christopher Raymond said. The positive results are the latest in a series of wins for Ardelyx.

  • Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
    PR Newswire

    Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive topline results from PHREEDOM, a long-term Phase 3 study evaluating the efficacy and safety of tenapanor as monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. In the study, patients randomized to the tenapanor arm were treated in a 26-week open-label treatment period and were then re-randomized to a 12-week double-blind, placebo-controlled randomized withdrawal period. The PHREEDOM study met its primary endpoint demonstrating a statistically significant difference in least square (LS) mean serum phosphorus change (-1.4 mg/dL, p<0.0001), as compared to placebo. During the 26-week treatment period, 77% of tenapanor-treated patients in the intent-to-treat population (n=408) had a decrease in serum phosphorus, with a mean reduction from baseline of 2.0 mg/dL. Tenapanor is an investigational, first-in-class, phosphate absorption inhibitor being developed to treat hyperphosphatemia in patients with CKD on dialysis. If approved, tenapanor will be the only non-binder treatment for the control of serum phosphorus in patients with CKD on dialysis.

  • Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
    PR Newswire

    Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study

    Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, announced that it will hold a conference call tomorrow, December 3, at 8:00 am Eastern Time to review the results from the pivotal Phase 3 PHREEDOM study evaluating tenapanor in chronic kidney disease (CKD) patients on dialysis. Tenapanor is Ardelyx's investigational, first-in-class, small molecule, non-binder, phosphate absorption inhibitor.

  • Benzinga

    The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...

  • Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference
    PR Newswire

    Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference

    Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019 at 2:00 p.m. ET in New York City.

  • Benzinga

    The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 25.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...

  • Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
    PR Newswire

    Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements

    Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases and Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based Global Specialty Pharmaceutical Company, today announced the expansion of their partnership with two new agreements.

  • Ardelyx Announces Presentation at Kidney Week 2019
    PR Newswire

    Ardelyx Announces Presentation at Kidney Week 2019

    Late breaking oral presentation to highlight data from AMPLIFY, the Pivotal Phase 3 Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment ...

  • Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
    PR Newswire

    Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights

    PHREEDOM clinical trial to read out this quarter FREMONT, Calif. , Nov. 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class ...

  • Why Ardelyx, Inc.'s (NASDAQ:ARDX) CEO Pay Matters To You
    Simply Wall St.

    Why Ardelyx, Inc.'s (NASDAQ:ARDX) CEO Pay Matters To You

    Mike Raab became the CEO of Ardelyx, Inc. (NASDAQ:ARDX) in 2009. This report will, first, examine the CEO compensation...

  • Ardelyx to Host Analyst Day in New York
    PR Newswire

    Ardelyx to Host Analyst Day in New York

    Management to Review Late Stage Clinical Development and Commercial Potential in Hyperphosphatemia, Pipeline Program in Hyperkalemia and Recent Approval in IBS-C FREMONT, Calif. , Oct. 10, 2019 /PRNewswire/ ...

  • Benzinga

    Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

    September turned out to be a fruitful month for FDA approvals. The regulatory agency gave its nod to Ardelyx Inc (NASDAQ: ARDX )'s Ibsrela, a new molecular entity indicated to treat irritable bowel syndrome ...

  • Some Ardelyx (NASDAQ:ARDX) Shareholders Have Taken A Painful 73% Share Price Drop
    Simply Wall St.

    Some Ardelyx (NASDAQ:ARDX) Shareholders Have Taken A Painful 73% Share Price Drop

    It is doubtless a positive to see that the Ardelyx, Inc. (NASDAQ:ARDX) share price has gained some 93% in the last...